Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in cardiomyocytes | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 3504
Sealed predictions
- NALF2 in dopamine neurons, braakn/a → n/areceipt 3512
- NALF2 in oligodendrocytes, braakn/a → n/areceipt 3511
Swarm cases
receipt 3512: NALF2 in dopamine neurons, braak
- cell type
- NALF2 is not measured in dopamine neurons; looking elsewhere.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NALF2 in dopamine neurons.
case closed: nothing better to follow up.
receipt 3511: NALF2 in oligodendrocytes, braak
- cell type
- NALF2 is not measured in oligodendrocytes; looking elsewhere.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NALF2 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts